Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-1.50 Insider Own0.90% Shs Outstand173.41M Perf Week-3.50%
Market Cap28.15B Forward P/E- EPS next Y-0.33 Insider Trans-67.04% Shs Float172.74M Perf Month-11.44%
Income-255.70M PEG- EPS next Q-0.55 Inst Own94.31% Short Float2.31% Perf Quarter1.76%
Sales1.02B P/S27.72 EPS this Y32.10% Inst Trans6.46% Short Ratio3.19 Perf Half Y36.66%
Book/sh10.46 P/B15.34 EPS next Y84.40% ROA-11.90% Target Price179.82 Perf Year108.19%
Cash/sh5.10 P/C31.43 EPS next 5Y- ROE-14.10% 52W Range65.44 - 187.99 Perf YTD40.43%
Dividend- P/FCF- EPS past 5Y-9.20% ROI-11.80% 52W High-14.65% Beta1.34
Dividend %- Quick Ratio4.40 Sales past 5Y26.20% Gross Margin90.10% 52W Low145.19% ATR6.15
Employees1605 Current Ratio4.70 Sales Q/Q27.30% Oper. Margin-32.90% RSI (14)40.21 Volatility2.90% 3.60%
OptionableYes Debt/Eq0.00 EPS Q/Q75.10% Profit Margin-25.20% Rel Volume0.58 Prev Close161.80
ShortableYes LT Debt/Eq0.00 EarningsJul 30 AMC Payout- Avg Volume1.25M Price160.45
Recom2.20 SMA20-6.77% SMA50-3.29% SMA20022.21% Volume727,158 Change-0.83%
Jul-31-20Reiterated H.C. Wainwright Buy $175 → $200
Jul-24-20Downgrade Piper Sandler Overweight → Neutral
May-26-20Initiated JMP Securities Mkt Outperform $185
May-01-20Upgrade Guggenheim Neutral → Buy
May-01-20Reiterated Needham Buy $157 → $163
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Dec-03-19Resumed BofA/Merrill Neutral
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Oct-22-19Reiterated BofA/Merrill Underperform $58 → $83
Sep-27-19Upgrade Goldman Neutral → Buy $78 → $100
Aug-26-19Initiated BTIG Research Neutral
Jul-18-19Initiated Deutsche Bank Hold $79
Jul-17-19Upgrade Piper Jaffray Neutral → Overweight $64 → $75
Apr-11-19Initiated Stifel Hold $70
Aug-06-20 08:00AM  
Jul-31-20 08:32PM  
11:16AM  
Jul-30-20 05:15PM  
04:02PM  
Jul-28-20 06:23AM  
Jul-24-20 12:10PM  
Jul-23-20 12:33PM  
Jul-19-20 08:58AM  
Jul-12-20 01:20PM  
Jul-09-20 08:00AM  
Jul-06-20 10:28AM  
Jul-03-20 10:03AM  
Jun-30-20 07:41AM  
Jun-29-20 04:30PM  
Jun-23-20 09:00PM  
Jun-22-20 11:00AM  
08:12AM  
Jun-18-20 08:00AM  
Jun-09-20 06:11PM  
Jun-03-20 08:00AM  
May-30-20 11:31AM  
May-29-20 08:00AM  
May-22-20 07:00PM  
May-19-20 01:02PM  
May-15-20 01:20PM  
11:20AM  
May-14-20 08:00AM  
May-13-20 05:12PM  
May-12-20 08:00AM  
May-09-20 02:19PM  
May-08-20 10:39AM  
May-07-20 05:42PM  
May-06-20 11:34AM  
May-05-20 08:00AM  
May-04-20 01:25PM  
11:45AM  
May-01-20 02:30PM  
Apr-30-20 05:15PM  
04:02PM  
11:12AM  
Apr-29-20 12:00PM  
10:05AM  
Apr-28-20 12:11PM  
Apr-24-20 08:00AM  
Apr-23-20 12:32PM  
Apr-22-20 02:20PM  
10:00AM  
Apr-21-20 12:34PM  
Apr-20-20 11:42AM  
07:21AM  
Apr-17-20 02:46PM  
02:27PM  
02:08PM  
Apr-16-20 04:38PM  
Apr-13-20 08:00AM  
Apr-08-20 09:59AM  
08:00AM  
Apr-07-20 08:29AM  
Apr-03-20 12:06PM  
Apr-02-20 04:44PM  
04:37PM  
11:04AM  
08:00AM  
Mar-17-20 05:54PM  
08:59AM  
Mar-10-20 08:00AM  
Mar-07-20 11:30AM  
Mar-02-20 08:00AM  
Feb-26-20 08:00AM  
Feb-19-20 05:12PM  
09:21AM  
08:28AM  
08:12AM  
Feb-13-20 08:00AM  
Feb-12-20 09:18AM  
Feb-11-20 08:00AM  
Feb-10-20 07:01PM  
05:00PM  
10:51AM  
09:37AM  
Feb-07-20 11:15AM  
Feb-06-20 05:25PM  
05:07PM  
04:02PM  
02:30PM  
Feb-05-20 09:45AM  
Jan-31-20 08:00AM  
Jan-30-20 12:31PM  
Jan-21-20 06:13PM  
08:30AM  
08:00AM  
Jan-20-20 09:32AM  
Jan-16-20 08:56AM  
Jan-09-20 04:24PM  
Jan-06-20 08:00AM  
Dec-30-19 10:09AM  
Dec-26-19 08:13PM  
02:47PM  
Dec-24-19 01:12PM  
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIMPSON TODD EChief Financial OfficerAug 03Sale165.7220,0003,314,418143,181Aug 05 07:14 PM
HIMES VAUGHN BChief Technical OfficerJul 17Option Exercise15.468,000123,680199,840Jul 21 07:48 PM
HIMES VAUGHN BChief Technical OfficerJul 17Sale179.428,0001,435,363191,840Jul 21 07:48 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.0028,472341,664734,660Jul 10 06:07 PM
SIEGALL CLAY BPresident and CEOJul 08Sale175.0828,4724,984,808718,339Jul 10 06:07 PM
ROMP CHARLES REVP, CommercialJul 02Sale167.49712119,25355,307Jul 07 06:34 PM
SIMPSON TODD EChief Financial OfficerJul 01Sale167.5811,5731,939,352163,181Jul 02 07:19 PM
LIU JEAN IGC/EVP, Leg AffairsJun 19Sale165.009,8771,629,70563,597Jun 22 07:46 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale158.892,162343,523109,608Jun 19 05:54 PM
DANSEY ROGER DChief Medical OfficerJun 16Sale157.15838131,692111,770Jun 17 07:24 PM
DANSEY ROGER DChief Medical OfficerJun 15Sale157.154,984783,236112,608Jun 17 07:24 PM
SIEGALL CLAY BPresident and CEOJun 08Option Exercise12.0028,472341,664724,939Jun 10 06:57 PM
SIEGALL CLAY BPresident and CEOJun 08Sale148.7728,4724,235,807718,339Jun 10 06:57 PM
BAKER BROS. ADVISORS LPDirectorMay 15Sale160.001,750,000280,000,0004,082,851May 19 06:03 PM
ROMP CHARLES REVP, CommercialMay 12Option Exercise15.466,942107,32359,517May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 12Sale166.006,9421,152,37252,575May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 08Option Exercise15.466,942107,32359,517May 08 07:54 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.0028,472341,664728,603May 12 07:51 PM
SIEGALL CLAY BPresident and CEOMay 08Sale161.0128,4724,584,311718,339May 12 07:51 PM
ROMP CHARLES REVP, CommercialMay 08Sale163.026,9421,131,66752,575May 08 07:54 PM
BAKER BROS. ADVISORS LPDirectorMay 08Sale158.50500,00079,250,0004,230,539May 08 05:47 PM
DANSEY ROGER DChief Medical OfficerMay 07Option Exercise65.1111,912775,590129,145May 08 07:42 PM
DANSEY ROGER DChief Medical OfficerMay 07Sale164.5011,9121,959,526117,233May 08 07:42 PM
BAKER BROS. ADVISORS LPDirectorMay 07Sale164.41168,24427,660,9474,272,736May 08 05:47 PM
SIEGALL CLAY BPresident and CEOMay 06Sale165.2325,4024,197,062718,339May 07 07:59 PM
WELCH DANIEL GDirectorMay 06Sale164.7915,0002,471,91955,263May 07 07:59 PM
BAKER BROS. ADVISORS LPDirectorMay 06Sale165.05390,07264,379,4734,286,935May 08 05:47 PM
SIMPSON TODD EChief Financial OfficerMay 05Option Exercise22.1539,059865,277188,563May 06 06:32 PM
AKKARAJU SRINIVASDirectorMay 05Option Exercise20.068,500170,51048,668May 07 07:58 PM
SIEGALL CLAY BPresident and CEOMay 05Sale166.0824,5984,085,341743,741May 07 07:59 PM
WELCH DANIEL GDirectorMay 05Sale166.7320,0003,334,64170,263May 07 07:59 PM
AKKARAJU SRINIVASDirectorMay 05Sale167.268,5001,421,71040,168May 07 07:58 PM
ROMP CHARLES REVP, CommercialMay 05Sale166.185,056840,22652,575May 07 07:59 PM
SIMPSON TODD EChief Financial OfficerMay 05Sale162.9426,8674,377,596161,696May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Option Exercise12.0014,167170,004175,863May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Sale147.0014,1672,082,556161,696May 06 06:32 PM
LIPPMAN MARC EDirectorMay 04Sale152.031,000152,030130,313May 06 06:19 PM
BAKER BROS. ADVISORS LPDirectorApr 23Option Exercise12.7635,000446,60045,860,149Apr 24 04:25 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.0028,472341,664779,866Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOApr 08Sale120.0128,4723,416,814758,784Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOMar 09Option Exercise12.0028,472341,664768,581Mar 11 06:51 PM
SIEGALL CLAY BPresident and CEOMar 09Sale110.0928,4723,134,578758,784Mar 11 06:51 PM
HIMES VAUGHN BChief Technical OfficerMar 06Option Exercise13.518,000108,117193,172Mar 10 08:12 PM
HIMES VAUGHN BChief Technical OfficerMar 06Sale114.918,000919,292188,674Mar 10 08:12 PM
DANSEY ROGER DChief Medical OfficerFeb 18Sale116.3335040,716107,659Feb 20 05:33 PM
SIEGALL CLAY BPresident and CEOFeb 10Option Exercise12.0028,472341,664768,723Feb 12 05:38 PM
SIEGALL CLAY BPresident and CEOFeb 10Sale114.6128,4723,263,110758,784Feb 12 05:38 PM
DANSEY ROGER DChief Medical OfficerFeb 03Sale108.5172778,887108,009Feb 05 06:08 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.0028,472341,664785,937Jan 10 07:08 PM
SIEGALL CLAY BPresident and CEOJan 08Sale111.3228,4723,169,433758,784Jan 10 07:08 PM
WELCH DANIEL GDirectorJan 07Option Exercise12.7617,500223,30090,263Jan 09 08:32 PM
DANSEY ROGER DChief Medical OfficerDec 16Sale114.072,000228,140101,146Dec 17 06:48 PM
SIEGALL CLAY BPresident and CEODec 09Option Exercise12.0028,472341,664773,011Dec 10 07:15 PM
SIEGALL CLAY BPresident and CEODec 09Sale114.5628,4723,261,641755,684Dec 10 07:15 PM
HIMES VAUGHN BChief Technical OfficerDec 06Option Exercise12.008,00096,000195,518Dec 10 07:14 PM
HIMES VAUGHN BChief Technical OfficerDec 06Sale117.168,000937,265187,518Dec 10 07:14 PM
DANSEY ROGER DChief Medical OfficerNov 25Option Exercise65.115,000325,550108,146Nov 27 05:32 PM
DANSEY ROGER DChief Medical OfficerNov 25Sale121.485,000607,388103,146Nov 27 05:32 PM
AKKARAJU SRINIVASDirectorNov 21Option Exercise19.0217,500332,85052,726Nov 22 06:35 PM
AKKARAJU SRINIVASDirectorNov 21Sale119.7817,5002,096,12040,168Nov 22 06:35 PM
LIPPMAN MARC EDirectorNov 18Option Exercise15.8935,000556,150148,813Nov 20 06:41 PM
DANSEY ROGER DChief Medical OfficerNov 18Option Exercise65.115,000325,550108,146Nov 20 06:45 PM
DANSEY ROGER DChief Medical OfficerNov 18Sale116.005,000580,000103,146Nov 20 06:45 PM
LIPPMAN MARC EDirectorNov 18Sale115.8035,0004,053,000131,313Nov 20 06:41 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.0028,472341,664776,483Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEONov 08Sale107.6128,4723,063,816755,684Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEOOct 08Option Exercise12.0028,472341,664770,104Oct 10 06:55 PM
SIEGALL CLAY BPresident and CEOOct 08Sale82.4728,4722,348,061755,684Oct 10 06:55 PM
GRYSKA DAVID WDirectorOct 01Option Exercise15.895,00079,45050,513Oct 03 07:38 PM
GRYSKA DAVID WDirectorOct 01Sale85.095,000425,45048,013Oct 03 07:38 PM
SIMPSON TODD EChief Financial OfficerSep 30Sale85.0015,0001,275,000157,567Oct 02 06:12 PM
LIU JEAN IGC/EVP, Leg AffairsSep 30Sale86.007,432639,15270,688Oct 02 06:10 PM
DANSEY ROGER DChief Medical OfficerSep 25Sale73.803,000221,415103,146Sep 27 06:12 PM
SIEGALL CLAY BPresident and CEOSep 09Option Exercise12.0028,472341,664774,374Sep 10 07:29 PM
SIEGALL CLAY BPresident and CEOSep 09Sale68.3328,4721,945,531755,684Sep 10 07:29 PM
HIMES VAUGHN BSee RemarksSep 03Sale70.805,692402,990187,518Sep 04 09:45 PM
SIEGALL CLAY BSee RemarksSep 03Sale70.809,693686,257755,684Sep 04 09:46 PM
DANSEY ROGER DSee RemarksSep 03Sale70.8092265,277106,146Sep 04 09:43 PM
SIMPSON TODD ESee RemarksSep 03Sale70.802,092148,112172,567Sep 04 09:42 PM
HIMES VAUGHN BSee RemarksAug 30Option Exercise12.008,00096,000201,210Sep 04 09:45 PM
HIMES VAUGHN BSee RemarksAug 30Sale72.868,000582,859193,210Sep 04 09:45 PM
LIU JEAN IGC/EVP, Leg AffairsAug 28Sale73.226,013440,24260,904Aug 30 04:35 PM
SIEGALL CLAY BPresident and CEOAug 28Sale73.2128,9512,119,636717,343Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 28Sale73.215,909432,624153,371Aug 30 04:36 PM
HIMES VAUGHN BChief Technical OfficerAug 28Sale73.216,836500,496175,197Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 20Sale80.0012,5001,000,000159,280Aug 22 05:49 PM
LIU JEAN IGC/EVP, Leg AffairsAug 20Sale80.003,716297,28066,917Aug 22 05:47 PM